Beacon's gene therapy for vision loss condition meets main trial goal

Beacon Therapeutics reported that its experimental gene therapy improved low-light reading ability in a late-stage trial for an inherited eye disease associated with progressive vision loss. The positive pivotal-stage efficacy result supports the therapy's development and potential regulatory path, though no detailed trial statistics or timeline were disclosed.